Drug intelligence / Profile preview

NVP-2102

Development stage: Phase 1
Lead developer: NVP Healthcare
Modality: Small Molecules
Administration: Oral

Overview

NVP-2102 is an orally administered small molecule drug under development by NVP Healthcare. Its precise mechanism of action is currently unknown. The drug has been evaluated in clinical studies to compare its pharmacokinetics and safety profile with a related compound, NVP-2102-R, primarily in healthy subjects. There are no FDA designations or approved indications reported for this compound at this time.

Beyond the preview

Go deeper on NVP-2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-2102.

Explore the full profile